568 related articles for article (PubMed ID: 26560120)
1. The SCF-type E3 Ubiquitin Ligases as Cancer Targets.
Kitagawa K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):119-29. PubMed ID: 26560120
[TBL] [Abstract][Full Text] [Related]
2. E3 Ubiquitin Ligases as Molecular Targets in Human Oral Cancers.
Masumoto K; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):130-5. PubMed ID: 26560119
[TBL] [Abstract][Full Text] [Related]
3. Skp1: Implications in cancer and SCF-oriented anti-cancer drug discovery.
Hussain M; Lu Y; Liu YQ; Su K; Zhang J; Liu J; Zhou GB
Pharmacol Res; 2016 Sep; 111():34-42. PubMed ID: 27238229
[TBL] [Abstract][Full Text] [Related]
4. E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma.
Bielskienė K; Bagdonienė L; Mozūraitienė J; Kazbarienė B; Janulionis E
Medicina (Kaunas); 2015; 51(1):1-9. PubMed ID: 25744769
[TBL] [Abstract][Full Text] [Related]
5. Regulation of GATA-binding protein 2 levels via ubiquitin-dependent degradation by Fbw7: involvement of cyclin B-cyclin-dependent kinase 1-mediated phosphorylation of THR176 in GATA-binding protein 2.
Nakajima T; Kitagawa K; Ohhata T; Sakai S; Uchida C; Shibata K; Minegishi N; Yumimoto K; Nakayama KI; Masumoto K; Katou F; Niida H; Kitagawa M
J Biol Chem; 2015 Apr; 290(16):10368-81. PubMed ID: 25670854
[TBL] [Abstract][Full Text] [Related]
6. Role of SKP1-CUL1-F-box-protein (SCF) E3 ubiquitin ligases in skin cancer.
Xie CM; Wei W; Sun Y
J Genet Genomics; 2013 Mar; 40(3):97-106. PubMed ID: 23522382
[TBL] [Abstract][Full Text] [Related]
7. Targeting SCF E3 Ligases for Cancer Therapies.
Liu J; Peng Y; Zhang J; Long J; Liu J; Wei W
Adv Exp Med Biol; 2020; 1217():123-146. PubMed ID: 31898226
[TBL] [Abstract][Full Text] [Related]
8. Stringent Control of NFE2L3 (Nuclear Factor, Erythroid 2-Like 3; NRF3) Protein Degradation by FBW7 (F-box/WD Repeat-containing Protein 7) and Glycogen Synthase Kinase 3 (GSK3).
Kannan MB; Dodard-Friedman I; Blank V
J Biol Chem; 2015 Oct; 290(43):26292-302. PubMed ID: 26306035
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of SCF ubiquitin ligases by engineered ubiquitin variants that target the Cul1 binding site on the Skp1-F-box interface.
Gorelik M; Orlicky S; Sartori MA; Tang X; Marcon E; Kurinov I; Greenblatt JF; Tyers M; Moffat J; Sicheri F; Sidhu SS
Proc Natl Acad Sci U S A; 2016 Mar; 113(13):3527-32. PubMed ID: 26976582
[TBL] [Abstract][Full Text] [Related]
10. Editorial: Ubiquitin E3 Ligases as Molecular Targets or Tools for Advanced Cancer Therapy.
Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):100. PubMed ID: 26791134
[No Abstract] [Full Text] [Related]
11. SCF
Cai L; Liu L; Li L; Jia L
Cell Signal; 2020 Jan; 65():109440. PubMed ID: 31678254
[TBL] [Abstract][Full Text] [Related]
12. Involvement of F-BOX proteins in progression and development of human malignancies.
Uddin S; Bhat AA; Krishnankutty R; Mir F; Kulinski M; Mohammad RM
Semin Cancer Biol; 2016 Feb; 36():18-32. PubMed ID: 26410033
[TBL] [Abstract][Full Text] [Related]
13. E3 ubiquitin ligase Fbw7 negatively regulates granulocytic differentiation by targeting G-CSFR for degradation.
Lochab S; Pal P; Kapoor I; Kanaujiya JK; Sanyal S; Behre G; Trivedi AK
Biochim Biophys Acta; 2013 Dec; 1833(12):2639-2652. PubMed ID: 23820376
[TBL] [Abstract][Full Text] [Related]
14. Isoform-specific SCF(Fbw7) ubiquitination mediates differential regulation of PGC-1α.
Trausch-Azar JS; Abed M; Orian A; Schwartz AL
J Cell Physiol; 2015 Apr; 230(4):842-52. PubMed ID: 25204433
[TBL] [Abstract][Full Text] [Related]
15. The tumor suppressor ING3 is degraded by SCF(Skp2)-mediated ubiquitin-proteasome system.
Chen G; Wang Y; Garate M; Zhou J; Li G
Oncogene; 2010 Mar; 29(10):1498-508. PubMed ID: 19935701
[TBL] [Abstract][Full Text] [Related]
16. The E3 ubiquitin ligase SCF(Fbxo7) mediates proteasomal degradation of UXT isoform 2 (UXT-V2) to inhibit the NF-κB signaling pathway.
Spagnol V; Oliveira CAB; Randle SJ; Passos PMS; Correia CRSTB; Simaroli NB; Oliveira JS; Mevissen TET; Medeiros AC; Gomes MD; Komander D; Laman H; Teixeira FR
Biochim Biophys Acta Gen Subj; 2021 Jan; 1865(1):129754. PubMed ID: 33010352
[TBL] [Abstract][Full Text] [Related]
17. Thiazolidinediones modulate the expression of beta-catenin and other cell-cycle regulatory proteins by targeting the F-box proteins of Skp1-Cul1-F-box protein E3 ubiquitin ligase independently of peroxisome proliferator-activated receptor gamma.
Wei S; Lin LF; Yang CC; Wang YC; Chang GD; Chen H; Chen CS
Mol Pharmacol; 2007 Sep; 72(3):725-33. PubMed ID: 17569795
[TBL] [Abstract][Full Text] [Related]
18. The FBXW7-NOTCH interactome: A ubiquitin proteasomal system-induced crosstalk modulating oncogenic transformation in human tissues.
Kar R; Jha SK; Ojha S; Sharma A; Dholpuria S; Raju VSR; Prasher P; Chellappan DK; Gupta G; Kumar Singh S; Paudel KR; Hansbro PM; Kumar Singh S; Ruokolainen J; Kesari KK; Dua K; Jha NK
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1369. PubMed ID: 33822486
[TBL] [Abstract][Full Text] [Related]
19. RING-, HECT-, and RBR-type E3 Ubiquitin Ligases: Involvement in Human Cancer.
Uchida C; Kitagawa M
Curr Cancer Drug Targets; 2016; 16(2):157-74. PubMed ID: 26560116
[TBL] [Abstract][Full Text] [Related]
20. NEDD4: a promising target for cancer therapy.
Ye X; Wang L; Shang B; Wang Z; Wei W
Curr Cancer Drug Targets; 2014; 14(6):549-56. PubMed ID: 25088038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
